Wei JCC, Kim TH, Kishimoto M, et al. - Whether brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has efficacy and safety for treating patients suffering from axial spondyloarthritis (axSpA), was inquired in this multicentre, placebo-controlled phase 3 study in Japan, Korea and Taiwan. axSpA patients were randomly assigned 1:1 to receive subcutaneous brodalumab 210 mg (n = 80) or placebo (n = 79) at baseline, weeks 1 and 2 and every 2 weeks thereafter, during the 16-week double-blind span. The proportion of patients with Assessment of SpondyloArthritis International Society 40 response at week 16, was assessed as the primary endpoint. In patients experiencing active axSpA, a significant improvement at week 16 was shown to be conferred by brodalumab in this study. Brodalumab displayed a safety profile consistent with that observed in earlier global/Japanese psoriasis studies.